Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
DRD3 1814 LOXAPINE HYDROCHLORIDE CHEMBL1201060 antagonist ChemblInteractions
DRD3 1814 CHLORPROTHIXENE CHEMBL908 antagonist TdgClinicalTrial, ChemblInteractions, TEND, DrugBank 17139284, 17016423, 1830565
DRD3 1814 ROPINIROLE CHEMBL589 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank, TTD 11752352, 10641988, 18691132
DRD3 1814 AMOXAPINE CHEMBL1113 antagonist ChemblInteractions, DrugBank 16135699
DRD3 1814 RISPERIDONE CHEMBL85 antagonist PharmGKB, GuideToPharmacologyInteractions, DrugBank 7531353, 7520908
DRD3 1814 VILAZODONE CHEMBL439849 agonist GuideToPharmacologyInteractions
DRD3 1814 QUINPIROLE CHEMBL240773 agonist GuideToPharmacologyInteractions
DRD3 1814 CHEMBL27441 CHEMBL27441 antagonist GuideToPharmacologyInteractions
DRD3 1814 HALOPERIDOL CHEMBL54 antagonist, inverse agonist GuideToPharmacologyInteractions, ChemblInteractions
DRD3 1814 NEMONAPRIDE CHEMBL20734 antagonist GuideToPharmacologyInteractions
DRD3 1814 PROMAZINE CHEMBL564 antagonist GuideToPharmacologyInteractions
DRD3 1814 CHEMBL140184 CHEMBL140184 antagonist GuideToPharmacologyInteractions
DRD3 1814 CHEMBL65280 CHEMBL65280 antagonist GuideToPharmacologyInteractions
DRD3 1814 SULPIRIDE CHEMBL26 antagonist GuideToPharmacologyInteractions
DRD3 1814 LEVOMEPROMAZINE CHEMBL1764 antagonist TdgClinicalTrial, ChemblInteractions, TEND, DrugBank 15701205
DRD3 1814 THIORIDAZINE CHEMBL479 antagonist ChemblInteractions
DRD3 1814 APOMORPHINE HYDROCHLORIDE CHEMBL1616 agonist ChemblInteractions
DRD3 1814 DROPERIDOL CHEMBL1108 antagonist ChemblInteractions
DRD3 1814 PARDOPRUNOX CHEMBL2103832 partial agonist TdgClinicalTrial, ChemblInteractions
DRD3 1814 CHEMBL1774080 CHEMBL1774080 antagonist TTD
DRD3 1814 SARIZOTAN CHEMBL220808 agonist TTD
DRD3 1814 PNU-99194A CHEMBL16410 binder TTD
DRD3 1814 CHEMBL1697690 CHEMBL1697690 antagonist TTD
DRD3 1814 ROPINIROLE HYDROCHLORIDE CHEMBL1200411 agonist ChemblInteractions
DRD3 1814 ARIPIPRAZOLE CHEMBL1112 partial agonist, antagonist DrugBank 17848919
DRD3 1814 OLANZAPINE CHEMBL715 antagonist PharmGKB, TdgClinicalTrial, ChemblInteractions, TEND, DrugBank 11752352, 17848919
DRD3 1814 LISURIDE CHEMBL157138 agonist GuideToPharmacologyInteractions, DrugBank 18691132
DRD3 1814 EDROPHONIUM CHEMBL1104 agonist GuideToPharmacologyInteractions
DRD3 1814 ROTIGOTINE CHEMBL1303 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank 18691132
DRD3 1814 CHEMBL285755 CHEMBL285755 agonist GuideToPharmacologyInteractions
DRD3 1814 BROMOCRIPTINE CHEMBL493 agonist TdgClinicalTrial, GuideToPharmacologyInteractions
DRD3 1814 PERGOLIDE CHEMBL531 agonist GuideToPharmacologyInteractions
DRD3 1814 ROXINDOLE CHEMBL431367 agonist GuideToPharmacologyInteractions
DRD3 1814 TERGURIDE CHEMBL73151 agonist GuideToPharmacologyInteractions
DRD3 1814 MESORIDAZINE CHEMBL1088 antagonist GuideToPharmacologyInteractions
DRD3 1814 PROCHLORPERAZINE CHEMBL728 antagonist GuideToPharmacologyInteractions
DRD3 1814 ZOTEPINE CHEMBL285802 antagonist GuideToPharmacologyInteractions
DRD3 1814 PALIPERIDONE CHEMBL1621 antagonist DrugBank 7531353, 7520908
DRD3 1814 N-DESMETHYLCLOZAPINE CHEMBL845 TdgClinicalTrial, DrugBank
DRD3 1814 OLANZAPINE PAMOATE CHEMBL1201741 antagonist ChemblInteractions
DRD3 1814 DEXPRAMIPEXOLE CHEMBL249420 TdgClinicalTrial
DRD3 1814 CHEMBL165679 CHEMBL165679 antagonist TTD
DRD3 1814 CARIPRAZINE HYDROCHLORIDE CHEMBL2024517 modulator ChemblInteractions
DRD3 1814 CHEMBL239767 CHEMBL239767 antagonist TTD
DRD3 1814 CHLORPROMAZINE HYDROCHLORIDE CHEMBL1713 antagonist ChemblInteractions
DRD3 1814 MIRTAZAPINE CHEMBL654 DrugBank 15771415, 12109911, 3419539
DRD3 1814 LOXAPINE CHEMBL831 antagonist, binder GuideToPharmacologyInteractions, ChemblInteractions, DrugBank
DRD3 1814 CHEMBL97424 CHEMBL97424 agonist GuideToPharmacologyInteractions
DRD3 1814 QUINELORANE CHEMBL155731 agonist GuideToPharmacologyInteractions
DRD3 1814 PIRIBEDIL (CHEMBL1371770) CHEMBL1371770 agonist GuideToPharmacologyInteractions
DRD3 1814 FLUPENTIXOL CHEMBL54661 antagonist GuideToPharmacologyInteractions
DRD3 1814 NAFADOTRIDE CHEMBL286252 antagonist GuideToPharmacologyInteractions
DRD3 1814 FOLINIC ACID CHEMBL1232801 antagonist GuideToPharmacologyInteractions
DRD3 1814 SPIPERONE CHEMBL267930 antagonist GuideToPharmacologyInteractions
DRD3 1814 [3H]NEMONAPRIDE CHEMBL2261102 antagonist GuideToPharmacologyInteractions
DRD3 1814 YOHIMBINE CHEMBL15245 antagonist DrugBank 10611634
DRD3 1814 PARDOPRUNOX HYDROCHLORIDE CHEMBL2105649 DrugBank
DRD3 1814 MIANSERIN CHEMBL6437 binder DrugBank
DRD3 1814 AMISULPRIDE CHEMBL243712 antagonist TdgClinicalTrial, TEND, DrugBank 16696579, 11873706, 12404702
DRD3 1814 CHEMBL418854 CHEMBL418854 binder TTD
DRD3 1814 BROMOCRIPTINE MESYLATE CHEMBL1200503 agonist ChemblInteractions
DRD3 1814 THIORIDAZINE HYDROCHLORIDE CHEMBL1200916 antagonist ChemblInteractions
DRD3 1814 HALOPERIDOL LACTATE CHEMBL2096643 inverse agonist ChemblInteractions
DRD3 1814 ZIPRASIDONE CHEMBL708 TEND
DRD3 1814 GABAZINE BROMIDE CHEMBL303580 antagonist TTD
DRD3 1814 METHAMPHETAMINE CHEMBL1201201 PharmGKB
DRD3 1814 BIFEPRUNOX CHEMBL218166 TdgClinicalTrial
DRD3 1814 LOXAPINE SUCCINATE CHEMBL1201155 antagonist ChemblInteractions
DRD3 1814 PERGOLIDE MESYLATE CHEMBL1275 agonist ChemblInteractions
DRD3 1814 CABERGOLINE CHEMBL1201087 agonist GuideToPharmacologyInteractions, DrugBank 10641988, 18691132, 18992242
DRD3 1814 CLOZAPINE CHEMBL42 antagonist GuideToPharmacologyInteractions, DrugBank 17848919
DRD3 1814 APOMORPHINE CHEMBL53 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 11752352
DRD3 1814 DOPAMINE CHEMBL59 agonist GuideToPharmacologyInteractions
DRD3 1814 PRAMIPEXOLE CHEMBL301265 agonist PharmGKB, TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, TTD
DRD3 1814 BP-897 CHEMBL25236 agonist GuideToPharmacologyInteractions
DRD3 1814 CHEMBL1255588 CHEMBL1255588 antagonist GuideToPharmacologyInteractions
DRD3 1814 CHLORPROMAZINE CHEMBL71 antagonist GuideToPharmacologyInteractions, ChemblInteractions
DRD3 1814 ETICLOPRIDE CHEMBL8946 antagonist GuideToPharmacologyInteractions
DRD3 1814 CHEMBL1627081 CHEMBL1627081 antagonist GuideToPharmacologyInteractions
DRD3 1814 CHEMBL2397386 CHEMBL2397386 antagonist GuideToPharmacologyInteractions
DRD3 1814 PEROSPIRONE CHEMBL1472975 antagonist GuideToPharmacologyInteractions
DRD3 1814 RACLOPRIDE CHEMBL8809 antagonist GuideToPharmacologyInteractions
DRD3 1814 SERTINDOLE CHEMBL12713 antagonist GuideToPharmacologyInteractions
DRD3 1814 CHEMBL196677 CHEMBL196677 antagonist GuideToPharmacologyInteractions
DRD3 1814 ILOPERIDONE CHEMBL14376 antagonist TdgClinicalTrial, DrugBank 23545936
DRD3 1814 COCAINE CHEMBL370805 TdgClinicalTrial, TEND
DRD3 1814 PRAMIPEXOLE DIHYDROCHLORIDE CHEMBL542257 agonist ChemblInteractions
DRD3 1814 PROMAZINE HYDROCHLORIDE CHEMBL1200469 antagonist ChemblInteractions
DRD3 1814 HALOPERIDOL DECANOATE CHEMBL1200986 inverse agonist ChemblInteractions
DRD3 1814 ETILEVODOPA CHEMBL1823681 agonist TdgClinicalTrial, ChemblInteractions
DRD3 1814 TRIFLUOPERAZINE HYDROCHLORIDE CHEMBL1710 antagonist ChemblInteractions
DRD3 1814 ASENAPINE (CHEMBL3187365) CHEMBL3187365 TdgClinicalTrial
DRD3 1814 SARIZOTAN HYDROCHLORIDE CHEMBL2146110 agonist ChemblInteractions
DRD3 1814 CHEMBL85606 CHEMBL85606 antagonist TTD
DRD3 1814 MELEVODOPA CHEMBL1328898 TdgClinicalTrial
DRD3 1814 ERGOLOID MESYLATES CHEMBL2311030 agonist ChemblInteractions
DRD3 1814 REMOXIPRIDE CHEMBL22242 antagonist DrugBank 11325388
DRD3 1814 DOMPERIDONE CHEMBL219916 antagonist GuideToPharmacologyInteractions, DrugBank 8301582
DRD3 1814 CAPTODIAME CHEMBL2110809 agonist DrugBank 23863923
DRD3 1814 CARIPRAZINE CHEMBL2028019 partial agonist, agonist TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank 23320989
DRD3 1814 PIMOZIDE CHEMBL1423 antagonist GuideToPharmacologyInteractions, ChemblInteractions, DrugBank 8301582
DRD3 1814 LEVODOPA CHEMBL1009 agonist TdgClinicalTrial, ChemblInteractions, DrugBank 11978145, 18549347, 9633680
DRD3 1814 TIAPRIDE CHEMBL84158 blocker DrugBank 11520476

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
DRD3 rs6280 TT methylphenidate efficacy yes Positive response defined as Clinical Global Impression-Improvement (CGI-I) rating of 'much improved' or 'very much improved', and decrease in Aberrant Behavior Checklist-Hyperactivity subscale of >25% from baseline. This result was not significant when considering correction for multiple testing (p<0.002). Genotype TT is associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotypes CC + CT. 23856854 1184510520
DRD3 rs6280 T pramipexole efficacy yes Allele T is associated with increased response to pramipexole. 19396436 613977365
DRD3 rs6280 CC + CT risperidone efficacy yes as measured by decrease in ATEC score. Genotypes CC + CT is associated with increased response to risperidone in children with Autistic Disorder as compared to genotype TT. 19997080 655387218
DRD3 rs6280 T clozapine efficacy not stated Allele T is not associated with response to clozapine in people with Schizophrenia as compared to allele C. 20029384 608431045
DRD3 rs6280 C lithium efficacy not stated This is from a review article which does not give all the details. It says that no association was found between the SNP and lithium response, but it does not state exactly how the alleles were compared. Allele C is not associated with response to lithium in people with Bipolar Disorder as compared to allele T. 21047205 699639235
DRD3 rs6280 TT clozapine efficacy yes This association was found in carriers of the DRD1 rs686 G allele (gene-gene interaction analysis). Genotype TT is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes CC + CT. 21332319 827793137
DRD3 rs167770 AG duloxetine efficacy yes as measured by change in HAM-A score at 10-12 weeks. Genotype AG is associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotypes AA + GG. 22249355 827820216
DRD3 rs6280 T olanzapine efficacy no no p-value reported Allele T is not associated with response to olanzapine in people with Schizophrenia as compared to allele C. 19000940 1183689310
DRD3 rs6280 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele C is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714368
DRD3 rs963468 GG duloxetine efficacy yes as measured by change in HAM-A score at 10-12 weeks. Genotype GG is associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotypes AA + AG. 22249355 827820202
DRD3 rs3773679 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Please note that alleles have been complemented to the positive strand. Allele C is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714354
DRD3 rs324023 CT duloxetine efficacy yes as measured by change in HAM-A score at 10-12 weeks. Genotype CT is associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotypes CC + TT. 22249355 827820224
DRD3 rs324026 CC + CT duloxetine efficacy yes as measured by change in HAM-A score at 10-12 weeks. Genotypes CC + CT are associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotype TT. 22249355 827820232
DRD3 rs6280 CC + CT paroxetine efficacy yes Response was measured by a decrease in score on the Montgomery and Asberg Depression Rating Scale (MADRS). Patients were evaluated on this scale after 1, 2, 4 and 6 weeks of treatment. Patients with the CC + CT genotypes showed significantly greater reductions in MADRS scores after 1 and 2 weeks of treatment, as well as a significantly greater percent improvement in MADRS score from baseline after 2 weeks of treatment, compared to those with the TT genotype. Genotypes CC + CT are associated with increased response to paroxetine in people with Depressive Disorder, Major as compared to genotype TT. 22926616 981501374
DRD3 rs6280 C aripiprazole efficacy no T carriers had better numerical response for most measurements, but this result was not significant. Gly -> C; Ser -> T. Allele C is not associated with response to aripiprazole in people with Schizophrenia as compared to allele T. 19302829 981959406
DRD3 rs9817063 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele C is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714333
DRD3 rs6280 TT quetiapine metabolism/PK yes Text describes this comparison as Ser/Ser versus Gly. The rs number is the most commonly discussed in DRD3 Genotype TT is associated with increased clearance of quetiapine in healthy individuals as compared to genotypes CC + CT. 25025989 1447520509
DRD3 rs6280 CT + TT antipsychotics efficacy no Patients' psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS). Drugs prescribed were clozapine (58 patients), risperidone (28 patients), aripiprazole (25 patients), quetiapine (18 patients), olanzapine (12 patients), paliperidone (3 patients), ziprasidone (1 patient), fluphenazine (21 patients), zuclopenthixol (19 patients), amisulpride (13 patients), flupentixol (9 patients), promazine (7 patients), and haloperidol (3 patients). Genotypes CT + TT are not associated with response to antipsychotics in people with Schizophrenia as compared to genotype CC. 27287786 1448258562
DRD3 rs3732790 A opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele A is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714340
DRD3 rs963468 A opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele A is not associated with dose of opioids in people with Pain as compared to allele G. 21398039 1449714347
DRD3 rs2399496 A opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Note that it is unclear from either the paper or the given allele frequencies whether the alleles are on the positive or negative strand. Allele frequencies are therefore reported as given in the paper. Allele A is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714326
DRD3 rs324026 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele C is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714375
DRD3 rs6280 C risperidone efficacy no The C allele was initially significantly more frequent in patients designated as non-responders to risperidone (i.e. <50% reduction in PANSS score compared to the cohort average). However, significance was lost following correction for multiple testing. Allele C is associated with decreased response to risperidone in people with Schizophrenia as compared to allele T. 28696411 1450928113
DRD3 rs167771 A opioids dosage no Variant had no significant association with opioid dose in the development sample. Allele A is not associated with dose of opioids in people with Pain as compared to allele G. 21398039 1449714361